Business Context and Reporting Period
This Form 8-K is a current report filed by Cerecor Inc. (not Avalo Therapeutics, Inc.) on April 10, 2018, covering events occurring on April 5, 2018, and April 6, 2018. The company is a Delaware corporation and an emerging growth company focused on biopharmaceutical development.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance and executive compensation arrangements.
Material Changes and Corporate Actions
- Board Appointment: On April 6, 2018, the Board appointed Simon C. Pedder, Ph.D., as a Class III director. Dr. Pedder brings extensive experience in drug development, having previously served as CEO of Cellectar Biosciences and Chelsea Therapeutics, and held senior roles at Hoffmann-LaRoche.
- Executive Employment Agreement: On April 5, 2018, the Company entered into an employment agreement with Matthew V. Phillips, Chief Commercial Officer, effective retroactively to January 22, 2018.
Management Commentary, Risks, and Compensation Details
The filing details the compensation structure for Mr. Phillips and the independence status of Dr. Pedder.
- Mr. Phillips Compensation:
- Base Salary: $295,000 per year.
- Annual Bonus: Target of 35% of base salary (cash and/or equity).
- Termination Benefits: In the event of termination without "Cause" or for "Good Reason," Mr. Phillips is eligible for 12 months of continued base salary, full vesting of options, and COBRA premium coverage for up to one year.
- Covenants: Includes a six-month non-competition and one-year non-solicitation agreement post-termination.
- Dr. Pedder Independence: The Board determined Dr. Pedder satisfies NASDAQ and SEC independence requirements. There are no related party transactions or family relationships with other directors or officers.
Investor Verification Checklist
- Verify the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "Cause" and "Good Reason."
- Review the press release (Exhibit 99.1) for additional context on Dr. Pedder's strategic value to the Board.
- Confirm the Company's current cash position in the most recent 10-Q or 10-K to assess the impact of the new executive compensation obligations.
- Note that the filing explicitly states the information in Item 7.01 is not "filed" for purposes of Section 18 of the Exchange Act.